نتایج جستجو برای: hbsag variants

تعداد نتایج: 113345  

2017
Ming-Hui Li Lu Zhang Xiao-Jing Qu Yao Lu Ge Shen Shu-Ling Wu Min Chang Ru-Yu Liu Lei-Ping Hu Zhen-Zhen Li Wen-Hao Hua Shu-Jing Song Yao Xie

BACKGROUND Hepatitis B surface antigen (HBsAg) loss/seroconversion is considered to be the ideal endpoint of antiviral therapy and the ultimate treatment goal in chronic hepatitis B (CHB). This study aimed to assess the patterns of HBsAg kinetics in CHB patients who achieved HBsAg loss during the treatment of pegylated interferon (PEG-IFN) α-2a. METHODS A total of 150 patients were enrolled, ...

2012
Jerzy Jaroszewicz Thomas Reiberger Dirk Meyer-Olson Stefan Mauss Martin Vogel Patrick Ingiliz Berit Anna Payer Matthias Stoll Michael P. Manns Reinhold E. Schmidt Robert Flisiak Heiner Wedemeyer Markus Peck-Radosavljevic Jürgen Rockstroh Markus Cornberg

HBsAg clearance is associated with clinical cure of chronic hepatitis B virus (HBV) infection. Quantification of HBsAg may help to predict HBsAg clearance during the natural course of HBV infection and during antiviral therapy. Most studies investigating quantitative HBsAg were performed in HBV mono-infected patients. However, the immune status is considered to be important for HBsAg decline an...

Journal: :Antiviral therapy 2011
Jerzy Jaroszewicz Huy Ho Antoaneta Markova Katja Deterding Karsten Wursthorn Sandra Schulz Claus-Thomas Bock Hans L Tillmann Michael P Manns Heiner Wedemeyer Markus Cornberg

BACKGROUND Hepatitis B surface antigen (HBsAg) loss is the ultimate goal of antiviral therapy and its prediction may be important for treatment individualization. Quantitative HBsAg (qHBsAg) has been shown to predict response to interferon-α, but few studies have analysed qHBsAg during treatment with nucleoside/nucleotide analogues (NAs). Serum interferon-inducible protein-10 (IP-10) has been a...

Journal: :Journal of clinical microbiology 1999
B Weber A Bayer P Kirch V Schlüter D Schlieper W Melchior

The performance of hepatitis B virus (HBV) surface antigen (HBsAg) screening assays is continuously improved in order to reduce the residual risk of transfusion-associated hepatitis B. In a multicenter study, a new automated rapid screening assay, Elecsys HBsAg (Roche Diagnostics), was compared to well-established tests (Auszyme Monoclonal [overnight incubation] version B and IMx HBsAg [Abbott]...

Journal: :Viruses 2023

Hepatitis delta virus (HDV) is an obligate satellite of hepatitis B (HBV). Dual HDV/HBV infection associated with down-regulated HBV replication and fast progression to severe liver disease. Although HDV transmissible through exposure infected blood, data about in blood donors remain scarce. Between 2011 2021, 869,633 donations were collected from prequalified Dalian, China. In total, 1060 (0.1...

Journal: :Biomedical journal 2015
Chen-Chih Liao Chao-Wei Hsu Po-Wen Gu Chau-Ting Yeh Shi-Ming Lin Cheng-Tang Chiu

BACKGROUND Hepatitis B virus (HBV) infection is one of the infections with a highest prevalence in Taiwan. The most important marker is hepatitis B surface antigen (HBsAg). Using the new generation of HBsAg quantitative assay, HBsAg level may have good correlation with viral activity during different phases of chronic hepatitis B virus infection. This study was conducted to compare two assays o...

Journal: :Clinical and vaccine immunology : CVI 2013
Takayuki Minekawa Shizuka Takehara Masaharu Takahashi Hiroaki Okamoto

Hepatitis B virus (HBV) infections are sometimes overlooked when using commercial kits to measure hepatitis B virus surface antigen (HBsAg) due to their low sensitivities and reactivities to mutant strains of various genotypes. We developed an ultrasensitive bioluminescent enzyme immunoassay (BLEIA) for HBsAg using firefly luciferase, which is adaptable to a variety of HBsAg mutants, by combini...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید